17 completed, 1 terminated, 1 unknown, 1 withdrawn. 10 Phase 2, 6 Phase 1, 3 Phase 3, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Terminated 1, Withdrawn 1 |
| Phase 1 | 6 | Completed 5, Withdrawn 1 |
| Phase 3 | 3 | Completed 3 |
| Not applicable | 1 | Unknown 1 |
| Phase 4 | 1 | Completed 1 |
Follow Interferon Alfa-2A: new trials by email Literature Review of Interferon Alfa-2A trials Research Report on Interferon Alfa-2A
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs. Nucleotide Analog, Interferon Alfa-2A - Hepatitis B | Not applicable | Unknown | Sun Yat-sen University | 400 | 2018-12-01 | 2023-05-08 |
| Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis Interferon Alfa-2A, Cyclosporine Pill - Behçet Disease, Uveitis | Phase 3 | Completed | Peking Union Medical College Hospital | 28 | 2017-06-30 | 2021-02-23 |
| Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection TG-2349, Ribavirin, Interferon Alfa-2a - Hepatitis C, Chronic | Phase 2 | Completed | TaiGen Biotechnology Co., Ltd. | 25 | 2015-05-01 | 2023-07-14 |
| Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia Influenza Vaccine Trivalent Inactivated (TIV), Pegylated interferon (PEGrIFN-α, Pegasys), Interferon (IFNα, Roferon-A) - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2011-04-01 | 2012-08-03 | |
| A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). bevacizumab [Avastin], interferon alfa-2a - Renal Cell Cancer | Phase 2 | Completed | Hoffmann-La Roche | 146 | 2008-12-01 | 2015-05-27 |
| Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer RAD001(everolimus), interferon alfa-2a, bevacizumab - Carcinoma, Adenocarcinoma | Phase 2 | Completed | Novartis Pharmaceuticals | 365 | 2008-11-12 | 2017-03-20 |
| A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. bevacizumab [Avastin], Interferon alfa-2a, Vinblastine - Renal Cell Cancer | Phase 2 | Completed | Hoffmann-La Roche | 25 | 2007-09-01 | 2014-10-13 |
| Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone Pioglitazone, Interferon Alfa-2a, Ribavirin - Chronic Hepatitis C | Phase 2 | Completed | University Hospital, Geneva | 5 | 2007-01-01 | 2015-05-28 |
| Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines Interferon Alfa-2a - Cancer | Phase 2 | Terminated | Duke University | 11 | 2005-11-01 | 2014-07-25 |
| Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease Peginterferon alfa-2a, Interferon alfa-2a - Chronic Hepatitis C, End Stage Renal Disease | Phase 4 | Completed | National Taiwan University Hospital | 50 | 2005-07-01 | 2008-03-06 |
| High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV Peginterferon alfa-2a, Interferon alfa-2a, Ribavirin - Hepatitis C | Phase 3 | Completed | Foundation for Liver Research | 33 | 2003-02-01 | 2021-09-01 |
| A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV) Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a - HIV Infections, Hepatitis C | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 132 | 2000-11-01 | 2021-11-01 |
| Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma. Interferon Alfa-2a, Interleukin-2 - Carcinoma, Renal Cell | Phase 3 | Completed | Gruppo Oncologico Italiano di Ricerca Clinica | 310 | 1994-07-01 | 2013-07-10 |
| A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma Interferon alfa-2a, Zidovudine, Interferon alfa-n1 - Sarcoma, Kaposi, HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2021-11-04 | |
| Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection. Isotretinoin, Interferon alfa-2a - HIV Infections, Anus Neoplasms | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 98 | 2021-10-28 | |
| A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3 Interferon alfa-2a, Zidovudine, Zalcitabine - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2021-11-04 | |
| Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma Interferon alfa-2a, Zidovudine - Sarcoma, Kaposi, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2021-11-03 | |
| A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease Interferon alfa-2a, Zidovudine - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2021-11-02 | |
| A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma Interferon alfa-2a, Zidovudine, Interferon alfa-n1 - Sarcoma, Kaposi, HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | 2021-11-03 | |
| The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children Interferon alfa-2a, Zidovudine - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 52 | 2021-10-29 |
HIV Infections (8) · Acquired Immunodeficiency Syndrome (5) · AIDS-Related Complex (4) · Carcinoma, Renal Cell (4) · Hepatitis C, Chronic (4) · Sarcoma, Kaposi (3) · Hepatitis C (2) · Adenocarcinoma (1) · Anus Neoplasms (1) · Behcet Syndrome (1) · Carcinoma (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Influenza, Human (1) · Insulin Resistance (1)
National Institute of Allergy and Infectious Diseases (NIAID) (8) · Hoffmann-La Roche (2) · Duke University (1) · Foundation for Liver Research (1) · Gruppo Oncologico Italiano di Ricerca Clinica (1) · M.D. Anderson Cancer Center (1) · National Taiwan University Hospital (1) · Novartis Pharmaceuticals (1) · Peking Union Medical College Hospital (1) · Sun Yat-sen University (1) · TaiGen Biotechnology Co., Ltd. (1) · University Hospital, Geneva (1)
United States (9) · Germany (3) · Italy (3) · Netherlands (3) · Switzerland (3) · Taiwan (3) · China (2) · Czechia (2) · Russia (2) · United Kingdom (2) · Belgium (1) · Brazil (1) · Egypt (1) · Estonia (1) · Finland (1)
Fischl MA (2) · Amar Safdar, MD (1) · Carlo Buzio, Medicine (1) · Chan Xie (1) · Chen-Hua Liu, M.D. (1) · Critchlow C (1) · D Mildvan (1) · Diaz C (1) · Francesco Negro, Prof (1) · Kaplan LD (1) · Krown S (1) · M Fischl (1) · Michael Morse, MD (1) · Ming-Lung Yu (1)
PMID 15282352, PMID 15563253, PMID 15685543, PMID 15867490, PMID 16115185, PMID 16439867, PMID 20622678, PMID 23803225, PMID 25304727, PMID 25851632, PMID 37096802, PMID 37146227, PMID 38923559
2008 (1)